UGT1A6 is a phase II drug-metabolizing enzyme that catalyzes the glucuronidation of various endogenous and xenobiotic compounds. The enzyme demonstrates glucuronosyltransferase activity toward substrates including serotonin, diclofenac, and aspirin metabolites 12. UGT1A6 exhibits complex protein-protein interactions with other UGT1A isoforms (UGT1A1 and UGT1A4), forming both homodimers and heterodimers that can modulate enzymatic activities in substrate- and isoform-specific manners 1. The enzyme is expressed in multiple tissues, including renal proximal tubule epithelial cells and brain microsomes, contributing to extrahepatic drug metabolism 34. Clinically, UGT1A6 genetic polymorphisms significantly impact drug pharmacokinetics, particularly for valproic acid where homozygous variants (541A>G and 552A>C) result in significantly lower concentration-to-dose ratios compared to wild-type 56. These polymorphisms show high frequency in certain populations and may contribute to interindividual variability in drug response 6. Additionally, UGT1A6 plays a role in aspirin metabolism, with genetic variations potentially affecting aspirin intolerance risk 2. The enzyme's tissue-specific expression and genetic variability make it an important consideration for personalized medicine approaches.